COVID-19: A Message from Our CEO
"As the COVID-19 pandemic evolves, CSL remains committed to safeguarding our patients, our donors and our people. In keeping with our values-based culture, CSL has taken precautions to ensure our employees and our facilities remain safe so we can continue to deliver on our promise to patients and public health." - Paul Perreault, CEO & Managing Director, CSL Limited
We're committed to the fight against influenza
At Seqirus, we are driven by just one goal - to lessen the severity and impact of influenza, which can reach epidemic or even pandemic proportions with life-threatening consequences. Every year our influenza vaccines help protect millions of people. We find solutions to big, complex, challenging problems, and we see the results in the world around us. Then we do it all over again the following year.
Seqirus is one of the world’s largest influenza vaccine companies. We were created when our parent company, CSL Limited, acquired the Novartis influenza vaccine business and combined it with vaccine subsidiary, bioCSL.
This website is intended for people seeking information on Seqirus' worldwide business.
Our country sites can be located in our Worldwide Directory.
UK/FLU/0519/0080 August 2019